Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

Completed

Conditions studied: Prostatic Neoplasms, Castration-Resistant

In brief

Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.

Key facts

Study ID

NCT02899104

Run by

Bayer

People needed

200

Starts

2017-06-15

Expected to finish

2019-03-31

Last updated by the study team

2020-03-31

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart.
• Patients were at least 18 years of age as of the first diagnosis for mCRPC.
• Patients must have received at least one intravenous injection of Radium-223 (Xofigo).
• First injection of Radium-223 must have started between periods
• 1-January-2014 to 30-June-2014 or 15-November-2014 to present.
• Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.

You may not qualify if…

• Patients who received Radium-223 as part in an interventional clinical trial
• Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.

Where it is running

• Whippany — Whippany, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.